Altimmune ALT Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -230,461%+285,399pp | -515,860%-493,341pp | -22,518.5%-151,548pp | 129,029.4%+131,227pp | |
| Net margin | -214,861%+260,434pp | -475,295%-454,533pp | -20,762.2%-145,340pp | 124,577.9%+126,780pp | |
| EBITDA margin | -230,187.8%+284,482pp | -514,670%-491,847pp | -22,823.5%-152,154pp | 129,330.9%+131,516pp | |
| Returns | |||||
| Return on equity | -50.6%+9.3pp | -59.9%-13.2pp | -46.6%-2.6pp | -44.1%+1.6pp | |
| Return on assets | -42%+12.3pp | -54.3%-12.0pp | -42.4%-2.6pp | -39.8%+2.1pp | |
| Return on invested capital | -62%+77.6pp | -139.6%-2.0pp | -137.6%+53.9pp | -191.5%-36.8pp | |
| Efficiency | |||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | -0×0.0× | |
| Liquidity | |||||
| Current ratio | 18.5×+5.4× | 13.1×-4.2× | 17.3×+6.0× | 11.3×+0.1× | |
| Quick ratio | 18.5×+5.4× | 13.1×-4.2× | 17.3×+6.0× | 11.3×+0.1× | |
| Cash ratio | 2.9×-0.6× | 3.5×-7.6× | 11.1×+4.6× | 6.5×-3.9× | |
| Leverage | |||||
| Debt-to-equity | 0.2×+0.1× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0.1×+0.1× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -57.8×+11,406× | -11,463.6×-8,723× | -2,740.8×— | —— | |
| Per Share | |||||
| Book value per share | $2.55+46.7% | $1.74-52.3% | $3.65-7.7% | $3.95-18.1% | |
| Valuation | |||||
| Market capitalization | $558.14M-2.1% | $512.81M-15.2% | $604.45M-25.3% | $808.67M+122% | |
| Enterprise value | $495.27M-5.0% | $477.52M+1.6% | $469.96M-33.2% | $703.24M+298% | |
| Price / sales | 13,613.2×— | 25,640.4×+24,222× | 1,418.9×— | —— | |
| Price / book | 2×-2.0× | 4.2×+1.0× | 3.1×-1.3× | 4.4×+2.5× | |
| EV / sales | 8,989.3×-14,887× | 23,876.1×+22,773× | 1,103.2×— | —— | |
| Earnings yield | -16.3%-0.5pp | -18.5%-3.9pp | -14.6%-4.2pp | -10.5%+16.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Altimmune's ratios come from?
- Every ratio is computed from Altimmune's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
